Clinical trial
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
NCT04489771 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 13, 2020
- Completion date
- August 25, 2026
- Enrollment
- 154 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.